Compare · POAI vs ZBH
POAI vs ZBH
Side-by-side comparison of Predictive Oncology Inc. (POAI) and Zimmer Biomet Holdings Inc. (ZBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both POAI and ZBH operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ZBH is the larger of the two at $17.34B, about 1397.7x POAI ($12.4M).
- Over the past year, POAI is down 61.1% and ZBH is down 6.7% - ZBH leads by 54.3 points.
- ZBH has hit the wire 15 times in the past 4 weeks while POAI has been quiet.
- ZBH has more recent analyst coverage (25 ratings vs 2 for POAI).
- Company
- Predictive Oncology Inc.
- Zimmer Biomet Holdings Inc.
- Price
- $5.49-0.18%
- $88.50-1.27%
- Market cap
- $12.4M
- $17.34B
- 1M return
- -16.18%
- +11.15%
- 1Y return
- -61.06%
- -6.71%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 15
- Recent ratings
- 2
- 25
Predictive Oncology Inc.
Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company operates in three segments: Helomics, Soluble, and Skyline. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers STREAMWAY System, a wall-mounted fully automated system that disposes suction fluid providing uninterrupted performance for physicians while virtually eliminating healthcare workers' exposure to infectious fluids collected during surgical and other patient procedures, as well as proprietary cleaning fluid and filters to users of its systems. The company also provides contract research organization (CRO) and AI-driven predictive models of tumor drug response to improve clinical outcomes to assist pharmaceutical, diagnostic, and biotech industries; and soluble and stable formulations for proteins, including vaccines, antibodies, and other protein therapeutics, as well as develops tumor models for precision cancer therapy and drug development. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to diseases databases. The company sells its medical device products directly to hospitals and other medical facilities through employed sales representatives, independent contractors, and distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Zimmer Biomet Holdings Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Latest POAI
- SEC Form S-8 filed by Predictive Oncology Inc.
- Predictive Oncology Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Chief Executive Officer Vennare Raymond F covered exercise/tax liability with 2,373 shares, decreasing direct ownership by 27% to 6,418 units (SEC Form 4)
- Predictive Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Predictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
- SEC Form EFFECT filed by Predictive Oncology Inc.
- Predictive Oncology Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 424B3 filed by Predictive Oncology Inc.
- SEC Form 424B3 filed by Predictive Oncology Inc.
- Predictive Oncology Inc. filed SEC Form 8-K: Other Events
Latest ZBH
- SEC Form 4 filed by Officer Noor Jehanzeb
- Group President, Asia Pacific Yi Sang sold $413,216 worth of shares (5,000 units at $82.64), decreasing direct ownership by 16% to 27,251 units (SEC Form 4)
- Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form SD filed by Zimmer Biomet Holdings Inc.
- SEC Form 4 filed by Director Farrell Michael J.
- SEC Form 4 filed by Director Bernard Betsy J
- SEC Form 4 filed by Director Hilado Maria Teresa
- SEC Form 4 filed by Director Shapiro Louis
- SEC Form 4 filed by Director Kurdikar Devdatt